Stratz Th, Müller W
Hochrhein-Institut für Rehabilitationsforschung e.V., Bad Säckingen.
Fortschr Med Orig. 2002;120(1):17-20.
The 5-HT3-receptor antagonist tropisetron has a favourable effect on the pain, not only of primary but also of secondary fibromyalgia. In an open study, ten women with clinical and serological evidence of secondary fibromyalgia were treated with tropisetron. Treatment comprised a single daily injection of 5 mg tropisetron on five consecutive days. Prior to, and 7 and 14 days after, treatment, the patients rated their pain on the visual analog pain (VAP) scale.
Nine patients experienced a substantial reduction in pain, with the mean VAP score decreasing from 64.3 initially, to 31.9 on the 7th day. After 14 days, the average score was 33.3, that is, roughly the same as that recorded after 7 days; however, 3 patients indicated the reappearance of substantially greater pain.
On the basis of these preliminary results, it would appear to be worth initiating a double-blind study to investigate the effects of short-term i.v. treatment with tropisetron in a large, clearly defined patient population with secondary fibromyalgia.
5-羟色胺3受体拮抗剂托烷司琼不仅对原发性纤维肌痛的疼痛，而且对继发性纤维肌痛的疼痛都有良好效果。在一项开放性研究中，对10名有继发性纤维肌痛临床和血清学证据的女性患者用托烷司琼进行治疗。治疗方法为连续5天每天单次注射5毫克托烷司琼。在治疗前以及治疗后7天和14天，患者根据视觉模拟疼痛（VAP）量表对自身疼痛进行评分。
9名患者疼痛大幅减轻，VAP平均评分从最初的64.3降至第7天的31.9。14天后，平均评分为33.3，即与7天后记录的评分大致相同；然而，有3名患者表示疼痛再次大幅加剧。
基于这些初步结果，开展一项双盲研究以调查在明确界定的大量继发性纤维肌痛患者群体中短期静脉注射托烷司琼的效果似乎是值得的。
